Drug Profile
Research programme: mRNA therapeutics - Avacta/Moderna Therapeutics
Latest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator Avacta
- Developer Avacta; Moderna Therapeutics
- Class Proteins; RNA
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for research development in Unspecified in United Kingdom
- 28 Nov 2019 No recent reports of development identified for research development in Unspecified in USA